AGL 40.20 Decreased By ▼ -1.30 (-3.13%)
AIRLINK 129.11 Increased By ▲ 1.11 (0.87%)
BOP 6.60 Increased By ▲ 0.34 (5.43%)
CNERGY 4.03 Decreased By ▼ -0.10 (-2.42%)
DCL 8.45 Increased By ▲ 0.01 (0.12%)
DFML 41.25 Increased By ▲ 0.56 (1.38%)
DGKC 87.00 Decreased By ▼ -0.90 (-1.02%)
FCCL 33.35 Decreased By ▼ -0.75 (-2.2%)
FFBL 65.90 Decreased By ▼ -0.43 (-0.65%)
FFL 10.54 Decreased By ▼ -0.02 (-0.19%)
HUBC 110.70 Increased By ▲ 2.00 (1.84%)
HUMNL 15.23 Increased By ▲ 0.77 (5.33%)
KEL 4.78 Increased By ▲ 0.13 (2.8%)
KOSM 7.83 Increased By ▲ 0.50 (6.82%)
MLCF 41.90 Decreased By ▼ -0.82 (-1.92%)
NBP 60.50 Decreased By ▼ -0.34 (-0.56%)
OGDC 182.80 Increased By ▲ 3.83 (2.14%)
PAEL 25.36 Decreased By ▼ -0.34 (-1.32%)
PIBTL 6.26 Increased By ▲ 0.20 (3.3%)
PPL 147.81 Increased By ▲ 1.66 (1.14%)
PRL 24.56 Decreased By ▼ -0.35 (-1.41%)
PTC 16.24 Increased By ▲ 0.10 (0.62%)
SEARL 70.50 Increased By ▲ 0.30 (0.43%)
TELE 7.30 Increased By ▲ 0.08 (1.11%)
TOMCL 36.30 Increased By ▲ 0.10 (0.28%)
TPLP 7.85 Increased By ▲ 0.01 (0.13%)
TREET 15.30 Decreased By ▼ -0.29 (-1.86%)
TRG 51.70 Increased By ▲ 1.34 (2.66%)
UNITY 27.35 Increased By ▲ 0.45 (1.67%)
WTL 1.23 Decreased By ▼ -0.01 (-0.81%)
BR100 9,842 Increased By 47.4 (0.48%)
BR30 30,036 Increased By 389.6 (1.31%)
KSE100 92,520 Increased By 499.1 (0.54%)
KSE30 28,786 Increased By 121.7 (0.42%)

Spanish biotechnology firm Zeltia is in talks with three companies to sell the licence for its Kahalalide F drug to treat acute psoriasis, its chairman said on Monday. "We've decided that Kahalalide be used to treat psoriasis, where we've seen a very positive reaction," Jose Maria Fernandez Sousa told Reuters in an interview.
Kahalalide F is currently in Phase II trials for the treatment of acute psoriasis. It had originally been developed for use against lung cancer and melanoma, but Zeltia has decided not to pursue those applications.
Zeltia has decided to shift Kahalalide F for dermatological use as its cancer research unit PharmaMar focuses on its speciality: anti-cancer compounds derived from marine organisms. Yondelis, PharmaMar's star drug, is already sold to treat soft tissue sarcoma, a rare and usually fatal form of cancer that attacks muscles, fat or blood vessels.
Zeltia plans to submit Yondelis for the treatment of ovarian cancer to the EMEA (European Medicines Agency) between mid-November and mid-December, Fernandez Sousa said, with approval expected in 2009. "We should have approval by next year and start selling for ovarian cancer in the second half or by the end of next year," he said.
Partner Johnson & Johnson will file for FDA approval around the same time. If Yondelis is approved for ovarian cancer treatment, the drug will have a sales potential of 1 billion euros a year, a target which Fernandez-Sousa hopes to reach by 2012. "We don't have a crystal ball ... but the potential is there," he said.

Copyright Reuters, 2008

Comments

Comments are closed.